| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4a11679d3a91d63060848f361d2873c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5355 |
| filingDate |
2021-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41c68041aab39ba25bc4991a914c3893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e011c739c0794be6ad5d4b0d385a8bd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d27163e2b4078692ee0ac53175702c98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89b8798f2f2bd8863f3694f91ae03b01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f06409eed082624ea737c2a54c287e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2b9828ed38df2088b65e66c6b8dd2c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec12d33600e9c3e70d5c164cf9c9685c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_672f81bf6e6cd885bb815a3bc0a63e97 |
| publicationDate |
2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021177721-A1 |
| titleOfInvention |
Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present |
| abstract |
The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer in which a KRAS mutation and activated RON are present. Particularly, the pharmaceutical composition can be used as an anticancer drug which exhibits an excellent ability to induce the apoptosis of cancer cells having a KRAS G13 mutation or a KRAS G12 mutation and a RON mutation or tyrosine-phosphorylated RON. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11453683-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11702418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11548888-B2 |
| priorityDate |
2020-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |